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Abstract
Background:  The role of angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D)
polymorphism in modifying the response to treatment modalities in coronary artery disease is
controversial.
Methods: PubMed was searched and a database of 58 studies with detailed information regarding
ACE I/D polymorphism and response to treatment in coronary artery disease was created. Eligible
studies were synthesized using meta-analysis methods, including cumulative meta-analysis.
Heterogeneity and study quality issues were explored.
Results: Forty studies involved invasive treatments (coronary angioplasty or coronary artery by-
pass grafting) and 18 used conservative treatment options (including anti-hypertensive drugs, lipid
lowering therapy and cardiac rehabilitation procedures). Clinical outcomes were investigated by 11
studies, while 47 studies focused on surrogate endpoints. The most studied outcome was the
restenosis following coronary angioplasty (34 studies). Heterogeneity among studies (p < 0.01) was
revealed and the risk of restenosis following balloon angioplasty was significant under an additive
model: the random effects odds ratio was 1.42 (95% confidence interval:1.07–1.91). Cumulative
meta-analysis showed a trend of association as information accumulates. The results were affected
by population origin and study quality criteria. The meta-analyses for the risk of restenosis following
stent angioplasty or after angioplasty and treatment with angiotensin-converting enzyme inhibitors
produced non-significant results. The allele contrast random effects odds ratios with the 95%
confidence intervals were 1.04(0.92–1.16) and 1.10(0.81–1.48), respectively. Regarding the effect
of ACE I/D polymorphism on the response to treatment for the rest outcomes (coronary events,
endothelial dysfunction, left ventricular remodeling, progression/regression of atherosclerosis),
individual studies showed significance; however, results were discrepant and inconsistent.
Conclusion: In view of available evidence, genetic testing of ACE I/D polymorphism prior to clinical
decision making is not currently justified. The relation between ACE genetic variation and response
to treatment in CAD remains an unresolved issue. The results of long-term and properly designed
prospective studies hold the promise for pharmacogenetically tailored therapy in CAD.
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Background
Coronary artery disease (CAD), including its most severe
complication, myocardial infarction (MI), is a complex
disorder resulting from the interaction between genetic
and environmental factors. Despite extensive efforts using
the candidate gene approach or genome-wide linkage
studies, the responsible molecular and genetic determi-
nants remain largely unidentified [1,2]. Recently,
genome-wide association studies provided more convinc-
ing evidence for CAD-associated genomic loci, generating
cautious optimism for disentangling the disease patho-
physiology and defining novel targets for treatment [3].
CAD mortality has been falling consistently in western
countries, as a result of population-wide improvements in
cardiovascular risk factors and modern cardiology treat-
ments for CAD patients [4]. Nevertheless, a considerable
inter-individual variability in response to the various
treatment modalities for CAD, both invasive and pharma-
cological, has been described [5]. Given the large number
of interventions currently available for the treatment and
prevention of CAD and the large number of patients eligi-
ble to receive them, even small sources of variation in effi-
cacy and safety have important implications for public
health. An important source of variability in response to
treatment is attributed to the patient's genetic profile
[1,4,5].
Among the most studied genes for its implication in
pathogenesis of CAD and related outcomes is angiotensin
converting enzyme (ACE) gene, located on chromosome
17q23 [6-8]. The genetic polymorphism in intron 16,
characterized by an insertion (I) or a deletion (D) of a 287
noncoding base pair Alu repeat sequence (dbSNP
rs4646994) has been correlated with the levels of circulat-
ing, intracellular and heart tissue activity of ACE [9]. Apart
from conferring susceptibility, the ACE gene has been also
proposed to play a role in modifying the effect of various
treatments in CAD. This potential modifying role has
been investigated by numerous studies on several treat-
ment-outcome settings. However, the available evidence
published to date is weak, owing to sparseness of data or
disagreements among studies. The aim of this study is to
summarize the available ACE I/D and response-to-treat-
ment studies for CAD and, where applicable, to quantify
the effect size of the estimated risk associated with this
polymorphism by meta-analysis.
Methods
Selection of studies
A comprehensive search of the PubMed database from its
inception through March 2008 was conducted. We com-
bined search terms for ACE genotype and CAD. Search
terms included (ACE OR angiotensin converting enzyme)
AND (gene OR polymorphism OR genetic variant) AND
(myocardial infarction OR coronary artery disease OR cor-
onary heart disease OR ischemic heart disease OR myocar-
dial ischemia OR angina OR acute coronary syndrome).
The retrieved studies were manually screened to assess
their appropriateness for inclusion criteria. All references
cited in the studies were also reviewed to identify addi-
tional published articles not indexed in the PubMed data-
base. Case reports, editorials and review articles were
excluded. The search was restricted to English-language
articles of studies in humans.
The review included genetic association studies fulfilling
the following inclusion criteria: (1) providing cases diag-
nosed with CAD or cohorts followed for CAD develop-
ment, (2) using guideline-incorporated primary or
secondary prevention measures for CAD [10-13], (3)
investigating clinical outcomes of CAD (in primary or sec-
ondary prevention studies) or surrogate outcomes pre-
dicting clinical events in CAD patients, (4) providing
information on genotype frequency for ACE I/D polymor-
phism or estimated genetic effects on response to treat-
ment, and (5) using validated molecular methods for
genotyping. Studies investigating susceptibility, progres-
sion, severity or survival, irrespective of treatment effect,
were excluded from this review.
Data extraction
Two investigators (GK and EZ) independently extracted
data. The extracted data included information about the
study design characteristics, the assessed outcomes, the
cohort characteristics, the intervention used and finally,
the reported results. Disagreements were resolved through
consensus. The quality of each study was also critically
assessed by reporting a composite quality score to allow
comparison among studies.
Data synthesis – Statistical analysis
For each study, the statistical significance of the main
findings for each treatment-outcome group was recorded
or the respective odds ratios were calculated by the
extracted genotypic frequencies.
In the case of studies with similar outcome definition cri-
teria, identical intervention and available genotype fre-
quency for each group, a meta-analysis was performed
(see results). Three meta-analyses were performed to
investigate the association between ACE I/D and the risk
of restenosis after angioplasty for the allele contrast (D vs
I), the recessive (DD vs. ID/II), the dominant (DD/ID vs.
II), the additive (DD vs II) and the co-dominant (ID vs
DD/II) models. We calculated the overall odds ratio (OR)
with the corresponding 95% confidence interval (CI)
using the fixed effects (FE) and random effects (RE; DerSi-BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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monian and Laird) models. Statistical heterogeneity
across the various studies was tested with the use of Q-sta-
tistic [14]. A p value < 0.10 indicated a significant statisti-
cal heterogeneity across studies, allowing for the use of RE
model.
A cumulative and recursive cumulative meta-analysis was
also carried out [6,14]. Cumulative and recursive cumula-
tive meta-analyses provide a framework for updating a
genetic effect from all studies and a measure of how much
the genetic effect changes as evidence accumulates. Thus,
cumulative meta-analysis indicates the trend in estimated
risk effect and recursive cumulative meta-analysis indi-
cates the stability in risk effect. In cumulative meta-analy-
sis, studies were chronologically ordered by publication
year, then, the pooled ORs were obtained at the end of
each year, i.e. at each information step. In recursive cumu-
lative meta-analysis, the relative change in pooled OR in
each information step (pooled OR in next year/pooled
OR in current year) was calculated. A differential magni-
tude of effect comparing large versus small studies for the
allele contrast was verified using the Egger regression test
[15].
In addition to the main (or overall) analysis which
included all available data, a subgroup analysis for each
"race" was also performed. 'Racial' descent was catego-
rized into Caucasian descents (European and American
whites), East Asian descents, mixed and populations of
Turkish ancestry [14].
The impact of study quality was assessed by performing
subgroup analysis on studies with high quality and low
quality components. The following parameters were con-
sidered as quality components: A. Internal validity crite-
ria: homogeneous study group, blindness of genotyping,
registration of loss to follow up, genotyping procedure
(original procedure or use of Insertion-specific primers)
[16], genotyping replication with another protocol, blind-
ness and objectiveness of angiograms assessment. B. Data
description and analysis criteria: data by gender provided,
power calculations provided, overlapping with previous
studies, description of cases recruitment procedure,
assessment of gene-gene interactions, control for possible
clinical and other modifiers between genotypes, control
of co-interventions that bear on outcome for each geno-
type, availability of data, appropriate statistics-description
and discussion of possible genetic effects. High quality
studies were defined as studies that exceeded the median
quality score [6].
Analyses were performed using StatsDirect (StatsDirect
Ltd), Compaq Visual Fortran90, and GLIM3.77.44–50
[6].
Results
Eligible studies
The literature search identified 759 citations. All citations
identified through the literature search were independ-
ently screened by two investigators (GK and EZ) according
to the inclusion criteria. Two hundred fifty-nine articles
were retrieved and evaluated against the same criteria.
Data from 58 articles [17-74] that investigated the associ-
ation between ACE I/D polymorphism and response to
treatment in CAD met the inclusion criteria, and were
included in the review. Next, data from 28 studies [17-
26,29-37,42-46,49] met the meta-analysis eligibility crite-
ria and were included in the context of three meta-analy-
ses. Figure 1 presents a flow chart of retrieved studies and
studies excluded, with specification of reasons.
Summary statistics
Details from studies included in our database are pro-
vided in Table 1 and Additional file 1. The interventions
investigated were classified in two major categories: inva-
sive (40 studies) and conservative (18 studies). The inva-
sive treatments included coronary revascularization by
percutaneous transluminal coronary angioplasty (PTCA)
and coronary artery by-pass grafting (CABG). The conserv-
ative treatments included pharmacological interventions
(16 studies) or cardiac rehabilitation procedures (two
studies). The investigated outcomes were classified as clin-
ical (11 studies) or surrogate (47 studies). The popula-
tions enrolled were of Caucasian (39 studies), East Asian
(10 studies), mixed (six studies) or Turkish ancestry (three
studies). Regarding study designs, our database included
44 cohort studies, eight randomized controlled trials, five
cross-sectional and one retrospective study.
We now present the results for each intervention in turn.
Invasive treatment strategies
Percutaneous transluminal coronary angioplasty
Since the first reports of successful angioplasty of coronary
atherosclerotic lesions, restenosis has been encountered
as a significant limitation to the long-term efficacy of the
procedure. Restenosis is an angiographically-defined out-
come correlated with reduction in the quality of life and
increase in the morbidity or even the mortality of patients
[75]. Stenting has rapidly become the preferred method
for PTCA, since it has distinct advantages over balloon
angioplasty alone, including the reduction of the rate of
restenosis from 50% to 20% [76].
Restenosis has been fitted into the standard multifactorial
model of complex disease, although classical genetic epi-
demiological studies (twin or extended family studies)
needed to establish the heritability of the phenotype are
not practical and have not been conducted. Moreover,BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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Flow chart of retrieved studies and studies excluded, with specification of reasons Figure 1
Flow chart of retrieved studies and studies excluded, with specification of reasons.BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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Table 1: Summary information of studies included in the meta-analyses.
First author, 
Year, Country 
[ref]
Study design, 
duration of FU
Cohort description 
[No of patients (M/
F), Ethnicity, Mean 
Age (SD), inclusion 
criteria]
Restenosis 
definition criteria
Intervention Gene-gene 
interaction 
assessed? 
(gene)
Quality score
Balloon 
angioplasty
Volzke, 2000, 
Germany [17]
cohort
6 months
511 (388/123), 
Caucasians, 60.6 (8.6), 
CAD patients 
undergoing elective 
PTCA of a previously 
untreated native 
coronary artery
> 50% progression of 
the residual stenosis 
at FU
PTCA-balloon No 35
Yoshida, 1999, 
Japan [18]
cohort
5.21 (3.9) years
123 (nr), East Asians, 
58.2 (10.2), MI patients 
undergoing PTCA 
discharged from 
hospital at the start of 
FU
nr PTCA-balloon No 30
Kasi, 1996, Spain 
[19]
cohort
6 months
69 (57/12), Caucasians, 
58 (9.9), UA patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-balloon No 27
Kamitani, 1995, 
Japan [20]
cohort
6 months
103 (103/00), East 
Asians, 52 (1), Primary 
PTCA for MI patients
> 50% progression of 
the residual stenosis 
at FU
PTCA-balloon No 27
Samani, 1995, UK 
[21]
cohort
4 months
233 (194/39), nr, 56 
(1), single-vessel PTCA 
in the Subcutaneous 
Heparin and 
Angioplasty Restenosis 
Prevention (SHARP) 
study
> 50% progression of 
the residual stenosis 
at FU
PTCA-balloon No 34
van Bockxmeer, 
1995, Australia 
[22]
cohort
6 months
207 (170/37), 
Caucasians, 57 (9), 
CAD patients 
undergoing elective 
PTCA
> 50% progression of 
the residual stenosis 
at FU
PTCA-balloon Yes (APOE)3 3
Tsukada, 1997, 
Japan [23]
cohort
3 months
96 (nr), East Asians, 60 
(1.0), CAD patients 
undergoing elective 
PTCA
diameter stenosis > 
50% at FU
PTCA-balloon No 28
Beohar, 1995, 
USA [24]
cohort
3 months
89 (nr), Caucasians, 
63.9 (10), CAD 
patients undergoing 
elective PTCA
diameter stenosis > 
50% at FU
PTCA-balloon No 24
Zee, 2001, Spain 
[25]
cohort
6 months
342 (305/37), 
Caucasians, 58.9 (9.6), 
CAD patients 
undergoing PTCA
> 50% progression of 
the residual stenosis 
at FU
PTCA-balloon No 37
Ohishi, 1993, 
Japan [26]
cohort
6 months
82 (nr), East Asians, nr, 
MI patients undergoing 
primary PTCA
> 50% progression of 
the residual stenosis 
at FU
PTCA-balloon No 23
Hamon, 1998, 
France [37]
cohort
6 months
271 (229/42), 
Caucasians, 60 (10), 
CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-balloon Yes (AGT1R)3 4
Angioplasty 
with stent 
deployment
Amant, 1997, 
France [30]
cohort
6 months
146 (117/29), 
Caucasians, 60 (10) 
CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-STENT No 37BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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given the known importance of anatomical factors, proce-
dural factors and diabetes in determining the risk of reste-
nosis, any genetic effect seems a priori likely to be small
[77]. Despite the lack of high biological plausibility, sev-
eral studies have examined the risk of restenosis in associ-
ation with ACE I/D polymorphism.
Overall 34 studies investigating restenosis were included
(Table 1 and Additional file 1). Eleven studies used PTCA
with balloon angioplasty alone (PTCA-balloon) [17-
26,37], 12 studies used PTCA with bare-metal stent
deployment (PTCA-STENT) [29-36,43,45,46,49], nine
studies used PTCA and investigated the effect of concom-
Wijpkema, 2006, 
Netherlands [29]
cohort
9 months
2888 (2050/838), 
Caucasians, 62 (11), 
CAD patients 
undergoing elective 
PTCA
death from cardiac 
causes, MI 
attributable to target 
vessel and target 
vessel 
revascularization
PTCA-STENT Yes (AGT, AGT1R, 
AGT2R, HMOX1)
35
Gomma, 2002, 
UK [31]
cohort
6 months
205 (155/50), 
Caucasians, 59.4 (9.9), 
CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-STENT No 27
Ruy, 2002, Korea 
[32]
cohort
6 months
238 (178/60), East 
Asians, 59.5 (9.9), CAD 
patients undergoing 
PTCA
diameter stenosis > 
50% at FU
PTCA-STENT Yes (CYP11B2, 
AGT)
32
Ribichini, 2004, 
Italy [33]
cohort
6 months
897 (160/737), 
Caucasians, 61 (10), 
CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-STENT No 33
Taniguchi, 2001, 
Japan [34]
cohort
6 months
67 (50/17), East Asians, 
65.2 (9.7), CAD 
patients undergoing 
PTCA
> 50% progression of 
the residual stenosis 
at FU
PTCA-STENT No 23
Koch, 2000, 
Germany [35]
cohort
1 year
1850 (1458/392), 
Caucasians, 62.9 (10), 
CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-STENT No 40
Gurlek, 2000, 
Turkey [36]
cohort
6 months
132 (112/20), Turks, 53 
(9), CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-STENT No 29
Guneri, 2005, 
Turkey [43]
cohort
9 months (2.9)
94 (59/35), Turks, 59.6 
(9.9), CAD diabetic 
patients undergoing 
PTCA for stable angina 
pectoris
diameter stenosis > 
50% at FU
PTCA-STENT No 26
Angioplasty 
with ACEi 
treatment
Ribichini, 2003, 
Italy [42]
Cohort
6.3 (2.5) months
271 (nr), Caucasians, 
61 (10), CAD patients 
undergoing PTCA
diameter stenosis > 
50% at FU
PTCA-STENT + 
ACEi
No 35
Okamura, 1999, 
Japan [44]
cohort
6 months
97 (84/13), East Asians, 
60 (2), CAD patients 
undergoing PTCA for 
stable angina pectoris
diameter stenosis > 
50% at FU
PTCA-balloon + 
Imidapril 5 mg
No 29
Okumura, 2002, 
Japan [45]
cohort
6 months
92 (73/19), East Asians, 
64.3 (8.9), CAD 
patients undergoing 
PTCA
diameter stenosis > 
50% at FU
PTCA-STENT + 
Quinapril 18 mg
No 22
Ferrari, 2002, 
multicenter 
(Europe) [46]
cohort
6 months
154 (119/35), 
Caucasians, 61 (9.9), 
CAD patients 
undergoing PTCA
> 50% progression of 
the residual stenosis 
at FU
PTCA-STENT + 
ACEi
No 36
Jorgensen, 2001, 
Netherlands [49]
cohort
6 months
369 (293/76), 
Caucasians, 59 (43–73), 
CAD patients 
undergoing PTCA for 
stable angina
diameter stenosis > 
50% at FU
PTCA-STENT + 
ACEi
No 40
Abbreviations: DCA: directional coronary atherectomy, FU: follow-up, UA: unstable angina, MI: myocardial infarction, RCT: randomized controlled 
trial, ACEi: angiotensin converting enzyme inhibitors, nr: non-reported
Table 1: Summary information of studies included in the meta-analyses. (Continued)BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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itant administration of ACE inhibitors (ACEi) [42-50] and
two studies used directional coronary atherectomy fol-
lowed by PTCA [51,52]. The data from 28 studies [17-
26,29-37,42-46,49] meeting the meta-analysis eligibility
criteria were synthesized (Table 1). Since the biological
phenomena underlying restenosis after PTCA-balloon
and PTCA-STENT are distinct (negative remodeling due to
elastic recoil versus neointimal hyperplasia and inflam-
matory response, respectively) [78], separate meta-analy-
ses for PTCA-balloon (11 studies included: [17-26,37])
and PTCA-STENT (12 studies included: [29-
36,43,45,46,49]) were performed. Moreover, the interac-
tion between PTCA and ACEi treatment was evaluated in
the context of a third meta-analysis (five studies included:
[42,44-46,49]). The findings of the studies not-included
in the meta-analysis are presented in Additional file 1.
Main results, subgroup and sensitivity analyses
Table 2 and Figures 2a) and 2b) show the results for the
association between ACE I/D gene polymorphism and the
risk of restenosis after PTCA.
All studies investigating restenosis after PTCA-balloon
were included in the meta-analysis. The main analysis for
investigating the association between allele D and the risk
of restenosis after PTCA-balloon relative to the allele I,
revealed significant heterogeneity (p < 0.01) among stud-
ies and, the random effects pooled OR was significant (RE
OR 1.34(1.09–1.65)). The recessive and dominant mod-
els also showed significant association (RE OR =
1.42(1.07–1.91) and RE OR = 1.36(1.05–1.76), respec-
tively). The additive model produced significant associa-
tion (RE OR = 1.42(1.07–1.91)) and the co-dominant
model non-significant association (RE OR = 0.95(0.79–
1.15)) as it was anticipated. Thus, ACE I/D polymorphism
contributes to risk of restenosis under an additive model.
In subgroup analysis by "race", Caucasians showed lack of
significant heterogeneity (pQ = 0.58) and a marginal sig-
nificance for the allele contrast (FE OR = 1.16(1.02–
1.31)) whereas East Asians revealed significant heteroge-
neity among studies (pQ < 0.01) and non-significant
association (RE OR = 1.85(0.90–3.83)).
On the contrary, in the meta-analyses investigating the
risk of restenosis after PTCA-STENT or after PTCA and
treatment with ACEi, there was non-significant heteroge-
neity among studies (pQ > 0.10) and the association was
non-significant overall, for Whites and East Asians, under
any genetic model.
Potential Bias. The cumulative meta-analysis of the allelic
contrast for restenosis after PTCA-balloon showed a trend
of association as information accumulates (Figure 3). In
recursive cumulative meta-analysis, the relative change in
RE OR stabilized after 1996/1995 indicating that there is
sufficient evidence for supporting an association (Figure
4a). In contrast, analysis for restenosis after PTCA-STENT
showed that the association remained non-significant for
the whole period (Figure 3). In the recursive cumulative
meta-analysis, the relative change in RE OR did not stabi-
lize in a specific OR indicating the need of more evidence
for investigating the association (Figure 4b). The sub-
group analysis for study quality showed lack of significant
heterogeneity (pQ = 0.46) and produced non-significant
association (FE OR = 1.13(0.99–1.28)) in the case of
high-quality studies for PTCA-balloon. In contrast, low
quality studies showed significant heterogeneity (pQ =
0.05) and significant association (RE OR = 1.99(1.48–
2.69)) (Table 2). For PTCA-STENT studies, the subgroup
analysis by quality did not reveal any significant associa-
tions, though significant heterogeneity across low quality
studies was observed (pQ = 0.08). The Egger test for the
allele contrast indicated that there is differential magni-
tude of effect in large versus small studies (p < 0.08).
Coronary artery by-pass grafting
Two small-scale studies [53,54] investigated the risk of
atherosclerotic degeneration in venous grafts in associa-
tion with the ACE I/D polymorphism, but the reported
results are discrepant (Additional file 1). In a European
cohort of CAD patients treated with CABG, the ACE gen-
otype was an independent predictor of total and cardiac
mortality in two-year follow up, explaining 17.7% of car-
diac events, although a relationship of I/D polymorphism
with graft atherosclerosis was not investigated [55].
Conservative treatment strategies
The results are summarized in Additional file 1.
Anti-hypertensive therapy
Two primary prevention trials of CAD assessed the effect
of  ACE I/D on anti-hypertensive therapy and reported
non-significant results overall [57,58]. The GenHAT study
[57] found no differences for the primary endpoint of
fatal CAD and nonfatal MI across gene-drug strata. ACE I/
D polymorphism was found to be significant only in the
subgroup of women treated with lisinopril. In the
PROGRESS study that enrolled patients with history of
cerebrovascular disease, there were no ACE-genotype spe-
cific benefits of perindopril administration on the out-
come of fatal CAD and nonfatal MI [58]. A retrospective
study by Marciante et al. [59] was the first study to exam-
ine the role of haplotypic variation in ACE gene on pri-
mary prevention of MI. None of the examined ACE
haplotypes (capturing the I/D polymorphism) was associ-
ated with the risk of MI in pharmacologically treated
hypertensive patients.The effect of ACE I/D polymor-
phism and ACEi treatment on surrogate CAD outcomes
was investigated by eight studies [60-67] (Additional file
1). The reported results are diverse and inconsistent,BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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Table 2: Odds ratios and heterogeneity results for the genetic contrasts of ACE I/D gene polymorphism for restenosis a) after PTCA-
balloon, b) after PTCA-STENT, and c) after PTCA and treatment with ACE inhibitors.
a)
Genetic contrast Population Studies Fixed effects
OR(95%ci)
Random effects
OR(95%ci)
I2
(%)
p-value
Q-test
D vs.I All 11 1.23(1.09–1.38) 1.34(1.09–1.65) 61 < 0.01
Caucasians 7 1.16(1.02–1.31) 1.16(1.02–1.31) 0 0.58
East Asians 4 1.75(1.29–2.37) 1.85(0.90–3.83) 81 < 0.01
High quality 6 1.13(0.99–1.28) 1.13(0.99–1.28) 0 0.46
Low quality 5 1.99(1.48–2.69) 1.95(1.21–3.14) 59 0.05
DD vs. (DI+II) All 11 1.30(1.09–1.54) 1.42(1.07–1.91) 52 0.02
Caucasians 7 1.20(1.00–1.45) 1.20(1.00–1.45) 0 0.57
East Asians 4 2.29(1.38–3.80) 1.88(0.65–5.45) 70 0.02
High quality 6 1.17(0.96–1.41) 1.19(0.96–1.47) 14 0.32
Low quality 5 2.24(1.45–3.46) 2.15(1.12–4.10) 50 0.09
(DD+ID) vs. II All 11 1.32(1.08–1.61) 1.36(1.05–1.76) 27 0.19
Caucasians 7 1.23(0.98–1.54) 1.23(0.96–1.57) 10 0.35
East Asians 4 1.78(1.12–2.82) 1.87(0.98–3.58) 44 0.15
High quality 6 1.18(0.95–1.48) 1.18(0.92–1.51) 16 0.31
Low quality 5 2.27(1.38–3.72) 2.21(1.33–3.66) 0 0.62
DD vs.II All 11 1.30(1.09–1.54) 1.42(1.07–1.91) 52 0.02
Caucasians 7 1.20(1.00–1.45) 1.20(1.00–1.45) 0 0.57
East Asians 4 2.29(1.38–3.80) 1.88(0.65–5.45) 70 0.02
High quality 6 1.17(0.96–1.41) 1.19(0.96–1.47) 14 0.32
Low quality 5 2.24(1.45–3.46) 2.15(1.12–4.10) 50 0.09
ID vs. (DD+II) All 11 0.96(0.82–1.13) 0.95(0.79–1.15) 14 0.01
Caucasians 7 0.97(0.81–1.15) 0.95(0.77–1.18) 21 0.27
East Asians 4 0.94(0.61–1.45) 0.93(0.55–1.55) 26 0.26
High quality 6 0.98(0.82–1.17) 0.97(0.78–1.21) 29 0.22
Low quality 5 0.87(0.57–1.32) 0.87(0.56–1.36) 7 0.37
b)
Genetic contrast Population Studies Fixed effects
OR(95%ci)
Random effects
OR(95%ci)
I2
(%)
p-value
Q-test
D vs. I All 11 1.03(0.94–1.12) 1.04(0.92–1.16) 25 0.21
Caucasians 7 1.01(0.92–1.11) 1.01(0.92–1.11) 0 0.45
East Asians 2 0.87(0.61–1.26) 0.88(0.61–1.26) na 0.61
High quality 6 1.02(0.93–1.12) 1.02(0.93–1.12) 1 0.41
Low quality 5 1.05(0.84–1.31) 1.07(0.77–1.49) 52 0.08
DD vs. (DI+II) All 11 1.05(0.92–1.21) 1.07(0.92–1.24) 7 0.38
Caucasians 7 1.03(0.89–1.20) 1.05(0.88–1.26) 20 0.28
East Asians 2 1.18(0.61–2.27) 1.18(0.61–2.28) na 0.68
High quality 6 1.04(0.89–1.21) 1.07(0.87–1.32) 32 0.20
Low quality 5 1.16(0.82–1.65) 1.17(0.82–1.66) 0 0.56
(DD+ID) vs. II All 12 1.01(0.87–1.16) 0.96(0.79–1.18) 30 0.16
Caucasians 7 1.00(0.86–1.17) 1.00(0.86–1.16) 0 0.45
East Asians 3 0.67(0.42–1.06) 0.67(0.42–1.07) 0 0.88
High quality 6 1.02(0.88–1.19) 1.02(0.87–1.19) 0 0.43
Low quality 6 0.93(0.67–1.30) 0.99(0.58–1.68) 51 0.07
c)
Genetic contrast Population Studies Fixed effects
OR(95%ci)
Random effects
OR(95%ci)
I2
(%)
p-value
Q-test
D vs. I Whites 3 1.10(0.81–1.48) 1.10(0.81–1.48) 0 0.42
DD vs. (DI+II) Whites 3 1.50(0.97–2.28) 1.74(0.78–3.87) 42.8 0.17
(DD+ID) vs. II All 5 0.85(0.52–1.38) 0.86(0.43–1.74) 31.2 0.21
Whites 3 0.71(0.41–1.22) 0.70(0.41–1.22) 0 0.93
East Asians 2 1.64(0.57–4.74) 1.22(0.09–16.61) na 0.05BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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derived mainly from underpowered or non-randomised
studies.
Lipid lowering treatment
Regarding clinical outcomes, three randomized trials
failed to show any significant ACE genotype-statin treat-
ment interactions in primary [68] or secondary preven-
tion [70,71] of CAD (Additional file 1). Additionally, in
the observational Rotterdam study, non-significant asso-
ciations were reported overall, although a significant
interaction between the ACE gene and the use of statins
was observed in male participants [69]. Regarding the
angiographic assessment of CAD progression or regres-
sion after statin treatment, the ACE I/D genotype was
found to be a major modifier, with DD patients being
more likely to have definite regression of coronary lesions,
consistent with a greater reduction in low density lipopro-
tein cholesterol levels [71].
Cardiac rehabilitation
Two studies examined the role of ACE I/D polymorphism
in modifying the response of physical training in aerobic
and exercise capacity in CAD patients. Defoor et al. [73]
found a greater beneficial effect in patients with II geno-
type than in D allele carriers, while Iwanaga et al. [74]
reported no significant findings in their smaller study.
Discussion
In this review, we have explored a large and varied litera-
ture and have found a wide range of quality of evidence.
The studies reviewed offer inconclusive and in many cases
contradictory results. The most widely investigated out-
come was the restenosis post-PTCA. We conducted meta-
analyses to shed some light on the contradictory results, as
well as to decrease the uncertainty of the effect size of esti-
mated risk.
The risk of restenosis following PTCA-balloon was con-
sistent for the allele contrast, the recessive, the dominant
and additive models, though the results showed signifi-
cant heterogeneity. Heterogeneity may result from differ-
ences in sample selection (e.g., in age-at-onset, gender, or
diagnostic criteria), in genotyping methodology (two dif-
ferent genotyping procedures were used), or may be due
to real differences in populations (e.g., 'racial' descent) or
due to interactions with other unknown risk factors [14].
The results of the meta-analysis were affected by popula-
tion origin. Caucasians showed significance under the
allele contrast whereas East Asians produced non-signifi-
cant results. The lower frequency of the DD genotype in
East Asian populations, coupled with the small sample
size in most studies, imply that any negative conclusion
could be due to low statistical power. True race-specific
genetic effects could explain this pattern of results, since
functional analyses of variation in ACE gene have indi-
cated that different loci control ACE levels in particular
'racial' groups [79]. Nevertheless, any inconsistencies in
risk effects of ACE I/D on restenosis between Caucasian
and East Asians might be also due to race-related anatom-
ical differences of coronary arteries, since a smaller total
vessel diameter has been described for Asian populations
[80].
The need for cumulative and recursive cumulative meta-
analyses has already been highlighted [6]. The stability in
the relative changes in ORs indicates that there is enough
evidence to draw safe conclusions about the modifying
effect of ACE I/D polymorphism in restenosis post-PTCA.
However, the results of the subgroup analysis by quality
[6,81] make the robustness of the main analysis question-
able.
Regarding the ACE I/D polymorphism and the risk of res-
tenosis after PTCA-STENT or after PTCA and treatment
with ACEi, there was non-significant heterogeneity
among studies and the association was non-significant
overall and for all examined subgroups, under any genetic
model. Despite higher biological plausibility in the con-
text of the PTCA-STENT intervention (the renin-angi-
otensin-aldosterone system is considered to be more
implicated in the inflammatory processes of neointimal
growth underlying post-PTCA-STENT restenosis, rather
than in elastic recoil remodeling following PTCA-bal-
loon) [78], the ACE polymorphism was not associated
with higher restenosis risk. The instability of the RE OR in
the recursive cumulative meta-analysis indicated the need
of more evidence to draw safer conclusions.
Our analysis showed a differential magnitude of effect in
large versus small studies. Previous meta-analyses had
already highlighted that the pooled estimate based on
published literature, which favoured an association, was
probably distorted by publication bias toward positive
results [7,8]. However, our analysis was based on a sub-
stantially larger number of studies (including a total of
9945 patients vs 4631 and 3150 patients that were used in
previous meta-analyses [7,8], respectively), which
allowed investigation of ACE I/D and angioplasty interac-
tion in the context of three clinically relevant distinct
meta-analyses. The ACE I/D polymorphism was associ-
ated only with restenosis post-PTCA-balloon and contrary
to previous findings [8], the results for this association
showed significant heterogeneity. Our subgroup analysis
identified ethnicity as a potential factor contributing to
heterogeneity and highlighted the effect of study quality
on summary estimates, which had not been previously
addressed. Additionally, the studies on the ACE I/D and
restenosis following PTCA-STENT were not significantly
heterogeneous, contradicting previous findings [8],BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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Random effects (RE) odds ratio (OR) estimates with the corresponding 95% confidence interval (CI) of the allele contrast (ACE  D vs. I) for restenosis a) after PTCA-balloon, and b) after PTCA-STENT Figure 2
Random effects (RE) odds ratio (OR) estimates with the corresponding 95% confidence interval (CI) of the 
allele contrast (ACE D vs. I) for restenosis a) after PTCA-balloon, and b) after PTCA-STENT. The OR estimate of 
each study is marked with a solid black square. The size of the square represents the weight that the corresponding study 
exerts in the meta-analysis. The confidence intervals of pooled estimates are displayed as a horizontal line through the dia-
mond. The horizontal axis is plotted on a log scale.
0.5 1 2 5 10 0.2
Ohishi, 1993 [26] 3.40 (1.61, 7.36)
Kamitani, 1995 [20] 3.49 (1.75, 7.05)
Samani, 1996 [21] 1.09 (0.74, 1.59)
van Bockxmeer, 1995 [22] 1.29 (0.85, 1.97)
Beohar, 1995 [24] 1.63 (0.76, 3.42)
Kaski, 1996 [19] 1.18 (0.56, 2.49)
Tsukada, 1997 [23] 1.20 (0.55, 2.53)
Hamon, 1998 [37] 1.16 (0.80, 1.68)
Yoshida, 1999 [18] 0.88 (0.49, 1.55)
Volzke, 2000 [17] 1.37 (1.04, 1.81)
Zee, 2001 [25] 1.01 (0.82, 1.24)
                   Pooled 1.34 (1.09, 1.65)
OR (95% CI)
0.5 1 2 5 0.2
Amant, 1997 [30] 1.65 (0.90, 3.10)
Koch, 2000 [35] 0.96 (0.82, 1.12)
Gurlek, 2000 [36] 1.96 (1.16, 3.33)
Taniguchi, 2001 [34] 1.05 (0.44, 2.48)
Jorgensen, 2001 [49] 1.00 (0.64, 1.58)
Gomma, 2002 [31] 0.84 (0.54, 1.32)
Ruy, 2002 [32] 0.83 (0.54, 1.28)
Ferrari, 2002 [46] 0.79 (0.46, 1.38)
Ribichini, 2004 [33] 1.12 (0.90, 1.40)
Guneri, 2005 [43] 1.03 (0.54, 1.96)
Wijpkema, 2006 [29] 1.03 (0.86, 1.22)
                    Pooled 1.04 (0.92, 1.16)
OR (95% CI)BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
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although the instability of the RE OR in the recursive
cumulative meta-analysis indicated that this potential
association remains an unresolved issue.
All of the analyzed studies in the meta-analysis for PTCA-
STENT involved bare metal stents. Given the near-univer-
sal adoption of stenting as the default strategy for PTCA,
the ACE I/D polymorphism can not be considered as a
reliable genetic marker of restenosis after PTCA. Neverthe-
less, in the era of drug-eluting stents [82], late stent throm-
bosis emerges as a clinically important outcome that
probably merits at least equivalent attention to restenosis
in the design of future studies.
The treatment modalities in which ACE gene has been
investigated as a potential modifier gene are diverse and
not linked by common molecular mechanisms, thus
questioning the biological rationale underlying the selec-
tion of this candidate gene. The discrepancy of the
observed results regarding the clinical and surrogate out-
comes of the other interventions (Additional file 1) could
be due to a series of factors, including heterogeneity of
enrolled cases, outcome definition variability, genotyping
errors [16], limited statistical power, different study
designs and variable interventions (in terms of type, dose,
duration or timing). Downgrading the potential signifi-
cance of ACE I/D polymorphism in the pharmacogenetics
Cumulative meta-analysis of the allele contrast (ACE D vs. I) for restenosis a) after PTCA-balloon, and b) after PTCA-STENT Figure 3
Cumulative meta-analysis of the allele contrast (ACE D vs. I) for restenosis a) after PTCA-balloon, and b) after 
PTCA-STENT. The random effects pooled odds ratio (OR) with the corresponding 95% confidence interval (CI) at the end 
of each year-information step is shown.
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Recursive cumulative meta-analysis of the allele contrast (ACE D vs. I) for restenosis a) after PTCA-balloon, and b) after PTCA- STENT Figure 4
Recursive cumulative meta-analysis of the allele contrast (ACE D vs. I) for restenosis a) after PTCA-balloon, 
and b) after PTCA-STENT. The relative change in random effects pooled odds ratio (OR) in each information step (OR in 
next year/OR in current year) for the allele contrast is shown.
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of CAD, none of the six studies enrolling more than 1,000
individuals [29,35,40,57,58,68] reported significant
results on its respective outcomes.
Large, prospective studies with similar study designs,
detailed clinical records, standardised outcome defini-
tions, limited variability in subjects enrolled and interven-
tions used, are needed. Moreover, if researchers can make
their data on individual patients readily available,
adjusted estimates for the effects of modifiers (such as age
or gender) can also be analyzed.
Since the ACE I/D polymorphism is intronic, it is unlikely
that it is functional. Despite considerable effort, the pre-
cise location of the functional polymorphism, or poly-
morphisms, is still unknown [83]. Future studies utilizing
the HapMap tagging SNPs data, could provide useful
insights, regarding the disease-associated gene haplo-
types. So far, only one study [59] used the haplotype
approach reporting negative results. In addition, the effect
of epistatic loci interacting with ACE I/D remains a poorly
investigated issue [7]. Elucidating the modifying effect of
the renin-angiotensin-aldosterone system on response to
treatment to CAD would demand a multigene haplotype
approach searching for variation throughout this patho-
physiological pathway [84]. With the advent of 'agnostic'
genome-wide association studies, novel variants of
unprecedented biological suspicion can be unravelled by
properly designed and well-powered pharmacogenomic
studies [85].
Cost-effectiveness analyses are crucial inputs in pharma-
cogenetic studies prior implementation of genetic tests in
clinical practice [86]. Despite some promising initial
pharmacoeconomic investigations [87], the ACE I/D gen-
otype and treatment interactions in CAD are not repro-
ducible and convincing enough to justify clinical
implementation any time soon.
Conclusion
Many studies have tried to characterize the effects of ACE
I/D polymorphism on the response to treatment in CAD,
in the context of both interventional and conservative
therapeutic options for clinical and surrogate endpoints.
However, the reported results so far are discrepant and
inconsistent. In view of available evidence, genetic testing
of ACE I/D polymorphism prior to clinical decision mak-
ing is not currently justified. The relation between ACE
genetic variation and response to treatment in CAD
remains an unresolved issue. The results of long-term and
properly designed prospective studies hold the promise
for pharmacogenetically tailored therapy in CAD.
Abbreviations
All abbreviations are defined in the text.
Competing interests
Georgios Kitsios is Pfizer-Tufts Medical Center Research
Fellow in Clinical Research.
Authors' contributions
GK and EZ designed the study and drafted the manuscript.
GK and EZ extracted the data and EZ analyzed the data.
Both authors had equal contribution to the revised man-
uscript.
Additional material
Acknowledgements
Scientific support for this project was provided through the Tufts Clinical 
and Translational Science Institute (Tufts CTSI) under funding from the 
National Institute of Health/National Center for Research Resources (UL1 
RR025752). Points of view or opinions in this paper are those of the 
authors and do not necessarily represent the official position or policies of 
the Tufts CTSI.
References
1. Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh
SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, O'Donnell
CJ, American Heart Association Council on Epidemiology and Pre-
vention; American Heart Association Stroke Council; Functional
Genomics and Translational Biology Interdisciplinary Working
Group: Relevance of genetics and genomics for prevention
and treatment of cardiovascular disease: a scientific state-
ment from the American Heart Association Council on Epi-
demiology and Prevention, the Stroke Council, and the
Functional Genomics and Translational Biology Interdiscipli-
nary Working Group.  Circulation 2007, 115:2878-2901.
2. Zintzaras E, Kitsios G: Identification of chromosomal regions
linked to premature myocardial infarction: a meta-analysis
of whole-genome searches.  J Hum Genet 2006, 51:1015-1021.
3. Damani SB, Topol EJ: Future use of genomics in coronary artery
disease.  J Am Coll Cardiol 2007, 50:1933-1940.
4. Unal B, Critchley JA, Capewell S: Explaining the decline in coro-
nary heart disease mortality in England and Wales between
1981 and 2000.  Circulation 2004, 109:1101-1107.
5. Johnson JA, Cavallari LH: Cardiovascular pharmacogenomics.
Exp Physiol 2005, 90:283-289.
6. Zintzaras E, Raman G, Kitsios G, Lau J: Angiotensin-converting
enzyme insertion/deletion gene polymorphic variant as a
marker of coronary artery disease: a meta-analysis.  Arch
Intern Med 2008, 168:1077-1089.
7. Bonnici F, Keavney B, Collins R, Danesh J: Angiotensin converting
enzyme insertion or deletion polymorphism and coronary
restenosis: meta-analysis of 16 studies.  BMJ 2002, 325:517-520.
8. Agema WR, Jukema JW, Zwinderman AH, Wall EE van der: A meta-
analysis of the angiotensin-converting enzyme gene poly-
morphism and restenosis after percutaneous transluminal
coronary revascularization: evidence for publication bias.
Am Heart J 2002, 144:760-768.
9. Danser AH, Schalekamp MA, Bax WA, Brink AM van den, Saxena PR,
Riegger GA, Schunkert H: Angiotensin-converting enzyme in
Additional file 1
Summary information of studies not included in the meta-analyses. 
The data provided represent the extracted information from studies not 
considered in the meta-analyses.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-10-50-S1.doc]BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
Page 14 of 16
(page number not for citation purposes)
the human heart. Effect of the deletion/insertion polymor-
phism.  Circulation 1995, 92:1387-1388.
10. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey
DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff
AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr,
Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt
SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP,
Page RL, Riegel B, American College of Cardiology; American Heart
Association Task Force on Practice Guidelines (Writing Committee
to Revise the 2002 Guidelines for the Management of Patients With
Unstable Angina/Non-ST-Elevation Myocardial Infarction); American
College of Emergency Physicians; Society for Cardiovascular Angiog-
raphy and Interventions; Society of Thoracic Surgeons; American
Association of Cardiovascular and Pulmonary Rehabilitation; Society
for Academic Emergency Medicine: ACC/AHA 2007 guidelines
for the management of patients with unstable angina/non
ST-elevation myocardial infarction: a report of the Ameri-
can College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Writing Committee to Revise
the 2002 Guidelines for the Management of Patients With
Unstable Angina/Non ST-Elevation Myocardial Infarction):
developed in collaboration with the American College of
Emergency Physicians, the Society for Cardiovascular Angi-
ography and Interventions, and the Society of Thoracic Sur-
geons: endorsed by the American Association of
Cardiovascular and Pulmonary Rehabilitation and the Soci-
ety for Academic Emergency Medicine.  Circulation 2007,
116:e148-e304.
11. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasya-
mani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle
DL, Sloan MA, Smith SC Jr, 2004 Writing Committee Members, Anbe
DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL,
Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW,
Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007
Focused Update of the ACC/AHA 2004 Guidelines for the
Management of Patients With ST-Elevation Myocardial Inf-
arction: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guide-
lines: developed in collaboration With the Canadian Cardio-
vascular Society endorsed by the American Academy of
Family Physicians: 2007 Writing Group to Review New Evi-
dence and Update the ACC/AHA 2004 Guidelines for the
Management of Patients With ST-Elevation Myocardial Inf-
arction, Writing on Behalf of the 2004 Writing Committee.
Circulation 2008, 117:296-329.
12. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J,
Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr,
Gardin JM, O'Rourke RA, Williams SV, Smith SC Jr, Jacobs AK, Adams
CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL,
Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page
RL, Riegel B, Tarkington LG, Yancy CW, American College of Cardi-
ology; American Heart Association; American College of Cardiology/
American Heart Association Task Force on Practice Guidelines Writ-
ing Group: 2007 chronic angina focused update of the ACC/
AHA 2002 Guidelines for the management of patients with
chronic stable angina: a report of the American College of
Cardiology/American Heart Association Task Force on
Practice Guidelines Writing Group to develop the focused
update of the 2002 Guidelines for the management of
patients with chronic stable angina.  Circulation 2007,
116:2762-2772.
13. Fourth Joint Task Force of the European Society of Cardiology and
Other Societies on Cardiovascular Disease Prevention in Clinical
Practice (Constituted by representatives of nine societies and by
invited experts, Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell
G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Her-
rmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG,
Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer
W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Other experts
who contributed to parts of the guidelines:, Walma E, Fitzgerald T,
Cooney MT, Dudina A, European Society of Cardiology (ESC) Com-
mittee for Practice Guidelines (CPG), Vahanian A, Camm J, De Cate-
r i n a  R ,  D e a n  V ,  D i c k s t e i n  K ,  Funck-Brentano C, Filippatos G,
Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Ten-
dera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E,
Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J,
Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Ped-
ersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef
AF, Tokgözoglu L, Wiklund O, Zampelas A: European guidelines
on cardiovascular disease prevention in clinical practice:
executive summary.  Eur Heart J 2007, 28:2375-2414.
14. Zintzaras E, Lau J: Synthesis of genetic association studies for
pertinent gene-disease associations requires appropriate
methodological and statistical approaches.  J Clin Epidemiol
2008, 61:634-645.
15. Sterne JA, Egger M: Funnel plots for detecting bias in meta-
analysis: guidelines on choice of axis.  J Clin Epidemiol 2001,
54:1046-1055.
16. Shanmugam V, Sell KW, Saha BK: Mistyping ACE heterozygotes.
PCR Methods Appl 1993, 3:120-121.
17. Volzke H, Hertwig S, Rettig R, Motz W: The angiotensinogen
gene 235T variant is associated with an increased risk of res-
tenosis after percutaneous transluminal coronary angi-
oplasty.  Clin Sci (Lond) 2000, 99:19-25.
18. Yoshida M, Iwai N, Ohmichi N, Izumi M, Nakamura Y, Kinoshita M: D
allele of the angiotensin-converting enzyme gene is a risk
factor for secondary cardiac events after myocardial infarc-
tion.  Int J Cardiol 1999, 70:119-125.
19. Kasi JC, Zhang Y, Calvino R, Vazquez-Rodriguez JM, Castro-Beiras A,
Jeffery S, Carter N: Angiotensin-converting enzyme insertion/
deletion polymorphism and restenosis after coronary angi-
oplasty in unstable angina pectoris.  Am J Cardiol 1996,
77:875-877.
20. Kamitani A, Rakugi H, Higaki J, Ohishi M, Shi SJ, Takami S, Nakata Y,
Higashino Y, Fujii K, Mikami H: Enhanced predictability of myo-
cardial infarction in Japanese by combined genotype analy-
sis.  Hypertension 1995, 25:950-953.
21. Samani NJ, O'Toole L, Martin D, Rai H, Fletcher S, Lodwick D,
Thompson JR, Morice AH, Channer K, Woods KL: Insertion/dele-
tion polymorphism in the angiotensin-converting enzyme
gene and risk of and prognosis after myocardial infarction.  J
Am Coll Cardiol 1996, 28:338-344.
22. van Bockxmeer FM, Mamotte CD, Gibbons FA, Burke V, Taylor RR:
Angiotensin-converting enzyme and apolipoprotein E geno-
types and restenosis after coronary angioplasty.  Circulation
1995, 92:2066-2071.
23. Tsukada K, Ishimitsu T, Tsuchiya N, Horinaka S, Matsuoka H: Angi-
otensin-converting enzyme gene polymorphism and cardio-
vascular endocrine system in coronary angiography patients.
Jpn Heart J 1997, 38:799-810.
24. Beohar N, Damaraju S, Prather A, Yu QT, Raizner A, Kleiman NS,
Roberts R, Marian AJ: Angiotensin-I converting enzyme geno-
type DD is a risk factor for coronary artery disease.  J Investig
Med 1995, 43:275-280.
25. Zee RY, Fernandez-Ortiz A, Macaya C, Pintor E, Lindpaintner K,
Fernandez-Cruz A: Ace D/I polymorphism and incidence of
post-PTCA restenosis: a prospective, angiography-based
evaluation.  Hypertension 2001, 37:851-855.
26. Ohishi M, Fujii K, Minamino T, Higaki J, Kamitani A, Rakugi H, Zhao
Y, Mikami H, Miki T, Ogihara T: A potent genetic risk factor for
restenosis.  Nat Genet 1993, 5:324-325.
27. Hertwig S, Volzke H, Robinson DM, Motz W, Rettig R: Angi-
otensinogen M235T gene polymorphism and recurrent rest-
enosis after repeated percutaneous transluminal coronary
angiography.  Clin Sci (Lond) 2002, 103:101-106.
28. Mulder HJ, van Geel PP, Schalij MJ, van Gilst WH, Zwinderman AH,
Bruschke AV: DD ACE gene polymorphism is associated with
increased coronary artery endothelial dysfunction: the
PREFACE trial.  Heart 2003, 89:557-558.
29. Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinder-
man AH, Zijlstra F, Steege G van der, de Winter RJ, Doevendans PA,
Waltenberger J, Jukema JW, Tio RA: Restenosis after percutane-
ous coronary intervention is associated with the angiotensin-
II type-1 receptor 1166A/C polymorphism but not with pol-
ymorphisms of angiotensin-converting enzyme, angiotensin-
II receptor, angiotensinogen or heme oxygenase-1.  Pharmaco-
genet Genomics 2006, 16:331-337.
30. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N,
Hamon M, Richard F, Helbecque N, McFadden EP, Amouyel P, Ber-
trand ME: D allele of the angiotensin I-converting enzyme is a
major risk factor for restenosis after coronary stenting.  Cir-
culation 1997, 96:56-60.BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
Page 15 of 16
(page number not for citation purposes)
31. Gomma AH, Elrayess MA, Knight CJ, Hawe E, Fox KM, Humphries SE:
The endothelial nitric oxide synthase (Glu298Asp and -
786T&gt;C) gene polymorphisms are associated with coro-
nary in-stent restenosis.  Eur Heart J 2002, 23:1955-1962.
32. Ryu SK, Cho EY, Park HY, Im EK, Jang YS, Shin GJ, Shim WH, Cho SY:
Renin-angiotensin-aldosterone system (RAAS) gene poly-
morphism as a risk factor of coronary in-stent restenosis.
Yonsei Med J 2002, 43:461-472.
33. Ribichini F, Ferrero V, Matullo G, Feola M, Vado A, Camilla T, Guar-
rera S, Carturan S, Vassanelli C, Uslenghi E, Piazza A: Association
study of the I/D polymorphism and plasma angiotensin-con-
verting enzyme (ACE) as risk factors for stent restenosis.
Clin Sci (Lond) 2004, 107:381-389.
34. Taniguchi I, Yamazaki T, Wagatsuma K, Kurusu T, Shimazu Y,
Takikawa K, Yoshikawa M, Kageyama S, Mochizuki S: The DD gen-
otype of angiotensin converting enzyme polymorphism is a
risk factor for coronary artery disease and coronary stent
restenosis in Japanese patients.  Jpn Circ J 2001, 65:897-900.
35. Koch W, Kastrati A, Mehilli J, Bottiger C, von BN, Schomig A: Inser-
tion/deletion polymorphism of the angiotensin I-converting
enzyme gene is not associated with restenosis after coronary
stent placement.  Circulation 2000, 102:197-202.
36. Gurlek A, Gulec S, Karabulut H, Bokesoy I, Tutar E, Pamir G, Alpman
A, Toydemir R, Aras O, Oral D: Relation between the insertion/
deletion polymorphism of the angiotensin I converting
enzyme gene and restenosis after coronary stenting.  J Cardi-
ovasc Risk 2000, 7:403-407.
37. Hamon M, Amant C, Bauters C, Richard F, Helbecque N, Passard F,
McFadden EP, Lablanche JM, Bertrand ME, Amouyel P: Dual deter-
mination of angiotensin-converting enzyme and angiotensin-
II type 1 receptor genotypes as predictors of restenosis after
coronary angioplasty.  Am J Cardiol 1998, 81:79-81.
38. Hamon M, Amant C, Bauters C, Lablanche JM, Bertrand M, Amouyel
P: ACE polymorphism, a genetic predictor of occlusion after
coronary angioplasty.  Am J Cardiol 1996, 78:679-681.
39. Gross CM, Perrot A, Geier C, Posch MG, Hassfeld S, Kramer J,
Schmidt S, Derer W, Dietz R, Ozcelik C: Recurrent in-stent rest-
enosis is not associated with the angiotensin-converting
enzyme D/I, angiotensinogen Thr174Met and Met235Thr,
and the angiotensin-II receptor 1 A1166C polymorphism.  J
Invasive Cardiol 2007, 19:261-264.
40. Hamon M, Fradin S, Denizet A, Filippi-Codaccioni E, Grollier G,
Morello R: Prospective evaluation of the effect of an angi-
otensin I converting enzyme gene polymorphism on the long
term risk of major adverse cardiac events after percutane-
ous coronary intervention.  Heart 2003, 89:321-325.
41. Prisco D, Fatini C, Battaglini B, Gensini F, Fedi S, Falai M, Chioccioli
M, Gori AM, Margheri M, Gensini GF: Angiotensin converting
enzyme DD genotype affects the changes of plasma plas-
minogen activator inhibitor-1 activity after primary percuta-
neous transluminal coronary angioplasty in acute
myocardial infarction patients.  Int J Clin Lab Res 2000,
30:179-185.
42. Ribichini F, Wijns W, Ferrero V, Matullo G, Camilla T, Feola M, Guar-
rera S, Vado A, Piazza A, Uslenghi E: Effect of angiotensin-con-
verting enzyme inhibition on restenosis after coronary
stenting.  Am J Cardiol 2003, 91:154-158.
43. Guneri S, Baris N, Aytekin D, Akdeniz B, Pekel N, Bozdemir V: The
relationship between angiotensin converting enzyme gene
polymorphism, coronary artery disease, and stent resteno-
sis: the role of angiotensin converting enzyme inhibitors in
stent restenosis in patients with diabetes mellitus.  Int Heart J
2005, 46:889-897.
44. Okamura A, Ohishi M, Rakugi H, Katsuya T, Yanagitani Y, Takiuchi S,
Taniyama Y, Moriguchi K, Ito H, Higashino Y, Fujii K, Higaki J, Ogihara
T: Pharmacogenetic analysis of the effect of angiotensin-con-
verting enzyme inhibitor on restenosis after percutaneous
transluminal coronary angioplasty.  Angiology 1999, 50:811-822.
45. Okumura K, Sone T, Kondo J, Tsuboi H, Mukawa H, Tsuzuki M, Imai
H, Kamiya H, Mabuchi Y, Matsui H, Hayakawa T: Quinapril pre-
vents restenosis after coronary stenting in patients with
angiotensin-converting enzyme D allele.  Circ J 2002,
66:311-316.
46. Ferrari M, Mudra H, Grip L, Voudris V, Schachinger V, de Jaegere P,
Rieber J, Hausmann D, Rothman M, Koschyk DH, Figulla HR, OPTI-
CUS ACE Substudy: Angiotensin-converting enzyme insertion/
deletion polymorphism does not influence the restenosis
rate after coronary stent implantation.  Cardiology 2002,
97:29-36.
47. Koch W, Mehilli J, von BN, Bottiger C, Schomig A, Kastrati A: Angi-
otensin I-converting enzyme (ACE) inhibitors and restenosis
after coronary artery stenting in patients with the DD geno-
type of the ACE gene.  J Am Coll Cardiol 2003, 41:1957-1961.
48. Meurice T, Bauters C, Hermant X, Codron V, VanBelle E, Mc Fadden
EP, Lablanche J, Bertrand ME, Amouyel P: Effect of ACE inhibitors
on angiographic restenosis after coronary stenting (PARIS):
a randomised, double-blind, placebo-controlled trial.  Lancet
2001, 357:1321-1324.
49. Jorgensen E, Kelbaek H, Helqvist S, Jensen GV, Saunamaki K, Kastrup
J, Havndrup O, Bundgaard H, Kyst Madsen J, Christiansen M,
Andersen PS, Reiber JH: Predictors of coronary in-stent resten-
osis: importance of angiotensin-converting enzyme gene
polymorphism and treatment with angiotensin-converting
enzyme inhibitors.  J Am Coll Cardiol 2001, 38:1434-1439.
50. Toyofyuku M, Imazu M, Sumii K, Yamamoto H, Hayashi Y, Hiyama K,
Kohno N: Influence of angiotensinogen M253T gene polymor-
phism and an angiotensin converting enzyme inhibitor on
restenosis after percutaneous coronary intervention.  Athero-
sclerosis 2002, 160:339-344.
51. Haberbosch W, Bohle RM, Franke FE, Danilov S, henc-Gelas F, Braun-
Dullaeus R, Hölschermann H, Waas W, Tillmanns H, Gardemann A:
The expression of angiotensin-I converting enzyme in
human atherosclerotic plaques is not related to the deletion/
insertion polymorphism but to the risk of restenosis after
coronary interventions.  Atherosclerosis 1997, 130:203-213.
52. Canosi U, Angelica Merlini P, Bernardi F, Repetto A, Bramucci E, Fer-
rario M, Angoli L, Gnecchi M, Ferraresi P, Marchetti G, Tavazzi L,
Ardissino D: Angiotensin-converting enzyme insertion/dele-
tion polymorphism and risk of restenosis after directional
coronary atherectomy followed by stent implantation.
Thromb Haemost 2004, 91:795-800.
53. Dayi SU, Tartan Z, Terzi S, Kasikcioglu H, Uyarel H, Orhan G, Alper
AT, Ciloglu F, Cam N: Influence of angiotensin converting
enzyme insertion/deletion polymorphism on long-term total
graft occlusion after coronary artery bypass surgery.  Heart
Surg Forum 2005, 8:E373-E377.
54. Ortlepp JR, Janssens U, Bleckmann F, Lauscher J, Merkelbach-Bruse S,
Hanrath P, Hoffmann R: A chymase gene variant is associated
with atherosclerosis in venous coronary artery bypass grafts.
Coron Artery Dis 2001, 12:493-497.
55. Volzke H, Engel J, Kleine V, Schwahn C, Dahm JB, Eckel L, Rettig R:
Angiotensin I-converting enzyme insertion/deletion poly-
morphism and cardiac mortality and morbidity after coro-
nary artery bypass graft surgery.  Chest 2002, 122:31-36.
56. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ,
van Gilst WH: Vascular effects of quinapril completely depend
on ACE insertion/deletion polymorphism.  J Renin Angiotensin
Aldosterone Syst 2004, 5:130-134.
57. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C,
Miller MB, Black H, Eckfeldt JH: Pharmacogenetic association of
the angiotensin-converting enzyme insertion/deletion poly-
morphism on blood pressure and cardiovascular risk in rela-
tion to antihypertensive treatment: the Genetics of
Hypertension-Associated Treatment (GenHAT) study.  Cir-
culation 2005, 111:3374-3383.
58. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J,
Chapman N, Colman S, Leguennec S, MacMahon S, Neal B, Ohkubo
T, Woodward M, PROGRESS Collaborative Group: The ACE gene
I/D polymorphism is not associated with the blood pressure
and cardiovascular benefits of ACE inhibition.  Hypertension
2003, 42:297-303.
59. Marciante KD, Bis JC, Rieder MJ, Reiner AP, Lumley T, Monks SA,
Kooperberg C, Carlson C, Heckbert SR, Psaty BM: Renin-angi-
otensin system haplotypes and the risk of myocardial infarc-
tion and stroke in pharmacologically treated hypertensive
patients.  Am J Epidemiol 2007, 166:19-27.
60. Pinto YM, van Gilst WH, Kingma JH, Schunkert H: Deletion-type
allele of the angiotensin-converting enzyme gene is associ-
ated with progressive ventricular dilation after anterior
myocardial infarction. Captopril and Thrombolysis Study
Investigators.  J Am Coll Cardiol 1995, 25:1622-1626.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2009, 10:50 http://www.biomedcentral.com/1471-2350/10/50
Page 16 of 16
(page number not for citation purposes)
61. Zee RY, Solomon SD, Ajani UA, Pfeffer MA, Lindpaintner K: A pro-
spective evaluation of the angiotensin-converting enzyme D/
I polymorphism and left ventricular remodeling in the 'Heal-
ing and Early Afterload Reducing Therapy' study.  Clin Genet
2002, 61:21-25.
62. Kennon S, Barakat K, Hitman GA, Price CP, Mills PG, Ranjadayalan K,
Cooper J, Clark H, Timmis AD: Angiotensin-converting enzyme
inhibition is associated with reduced troponin release in non-
ST-elevation acute coronary syndromes.  J Am Coll Cardiol 2001,
38:724-728.
63. Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N,
Quyyumi AA: Insertion-deletion polymorphism of the ACE
gene modulates reversibility of endothelial dysfunction with
ACE inhibition.  Circulation 2000, 102:35-41.
64. Trevelyan J, Needham EW, Morris A, Mattu RK: Comparison of
the effect of enalapril and losartan in conjunction with surgi-
cal coronary revascularisation versus revascularisation alone
on systemic endothelial function.  Heart 2005, 91:1053-1057.
65. Pedersen OD, Gram J, Jeunemaitre X, Billaud E, Jespersen J: Does
long-term angiotensin converting enzyme inhibition affect
the concentration of tissue-type plasminogen activator-plas-
minogen activator inhibitor-1 in the blood of patients with a
previous myocardial infarction.  Coron Artery Dis 1997, 8:283-291.
66. Jeron A, Hengstenberg C, Engel S, Lowel H, Riegger GA, Schunkert
H, Holmer S: The D-allele of the ACE polymorphism is related
to increased QT dispersion in 609 patients after myocardial
infarction.  Eur Heart J 2001, 22:663-668.
67. Steeds RP, Fletcher J, Parry H, Chowdhary S, Channer KS, West J,
Townend JN: The angiotensin-converting enzyme gene I/D
polymorphism and heart rate variability following acute
myocardial infarction.  Clin Auton Res 2002, 12:66-71.
68. Zee AH Maitland-van der, Boerwinkle E, Arnett DK, Davis BR, Leien-
decker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH:
Absence of an interaction between the angiotensin-convert-
ing enzyme insertion-deletion polymorphism and pravasta-
tin on cardiovascular disease in high-risk hypertensive
patients: the Genetics of Hypertension-Associated Treat-
ment (GenHAT) study.  Am Heart J 2007, 153:54-58.
69. Zee AH Maitland-van der, Stricker BH, Klungel OH, Kastelein JJ, Hof-
man A, Witteman JC, Leufkens HG, Duijn CM, Boer AdA: Effective-
ness of HMG-CoA reductase inhibitors is modified by the
ACE insertion deletion polymorphism.  Atherosclerosis 2004,
175:377-379.
70. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moye LA, Pfeffer MA,
Sacks FM, Braunwald E: The platelet Pl(A2) and angiotensin-
converting enzyme (ACE) D allele polymorphisms and the
risk of recurrent events after acute myocardial infarction.
Am J Cardiol 2001, 88:347-352.
71. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM:
Interactions between angiotensin-I converting enzyme
insertion/deletion polymorphism and response of plasma lip-
ids and coronary atherosclerosis to treatment with fluvasta-
tin: the lipoprotein and coronary atherosclerosis study.  J Am
Coll Cardiol 2000, 35:89-95.
72. Talmud PJ, Watts GF, McBride S, Mandalia S, Brunt JN, Coltart DJ,
Lewis B, Humphries SE: Angiotensin converting enzyme gene
polymorphism and the course of angiographically defined
coronary artery disease.  Atherosclerosis 1995, 114:133-135.
73. Defoor J, Vanhees L, Martens K, Matthijs G, Van VA, Zielinska D,
Schepers D, Vlietinck R, Fagard R: The CAREGENE study: ACE
gene I/D polymorphism and effect of physical training on aer-
obic power in coronary artery disease.  Heart 2006, 92:527-528.
74. Iwanaga Y, Nishi I, Ono K, Takagi S, Tsutsumi Y, Ozaki M, Noguchi T,
Takak i H, Iw ai N, Nonogi H, Goto Y: Angiotensin-converting
enzyme genotype is not associated with exercise capacity or
the training effect of cardiac rehabilitation in patients after
acute myocardial infarction.  Circ J 2005, 69:1315-1319.
75. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Men-
ichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME,
Schömig A: Analysis of 14 trials comparing sirolimus-eluting
stents with bare-metal stents.  N Engl J Med 2007,
356:1030-1039.
76. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno
F, Colman T, Zueco J, Delcan JL, García E, Calabuig J: Randomized
comparison of coronary stent implantation and balloon angi-
oplasty in the treatment of de novo coronary artery lesions
(START): a four-year follow-up.  J Am Coll Cardiol 1999,
34:1498-1506.
77. Keavney B: Outcome following percutaneous coronary inter-
vention: not, so far, in our genes.  Heart 2003, 89:247-248.
78. Welt FG, Rogers C: Inflammation and restenosis in the stent
era.  Arterioscler Thromb Vasc Biol 2002, 22:1769-1776.
79. McKenzie CA, Abecasis GR, Keavney B, Forrester T, Ratcliffe PJ, Julier
C, Connell JM, Bennett F, McFarlane-Anderson N, Lathrop GM, Car-
don LR: Trans-ethnic fine mapping of a quantitative trait
locus for circulating angiotensin I-converting enzyme (ACE).
Hum Mol Genet 2001, 10:1077-1084.
80. Dhawan J, Bray CL: Are Asian coronary arteries smaller than
Caucasian? A study on angiographic coronary artery size
estimation during life.  Int J Cardiol 1995, 49:267-269.
81. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C,
Lau J: Correlation of quality measures with estimates of
treatment effect in meta-analyses of randomized controlled
trials.  JAMA 2002, 287:2973-2982.
82. Bavry AA, Bhatt DL: Appropriate use of drug-eluting stents:
balancing the reduction in restenosis with the concern of late
thrombosis.  Lancet 2008, 371:2134-2143.
83. Zhu X, Bouzekri N, Southam L, Cooper RS, Adeyemo A, McKenzie
CA, Luke A, Chen G, Elston RC, Ward R: Linkage and association
analysis of angiotensin I-converting enzyme (ACE)-gene pol-
ymorphisms with ACE concentration and blood pressure.
Am J Hum Genet 2001, 68:1139-1148.
84. Cordell HJ: Epistasis: what it means, what it doesn't mean, and
statistical methods to detect it in humans.  Hum Mol Genet
2002, 11:2463-2468.
85. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman
L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 vari-
ants and statin-induced myopathy – a genomewide study.  N
Engl J Med 2008, 359:789-799.
86. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effec-
tiveness of pharmacogenomics.  AAPS PharmSci 2000, 2:E29.
87. Zee AH Maitland-van der, Klungel OH, Stricker BH, Veenstra DL,
Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de
Boer A: Pharmacoeconomic evaluation of testing for angi-
otensin-converting enzyme genotype before starting beta-
hydroxy-beta-methylglutaryl coenzyme A reductase inhibi-
tor therapy in men.  Pharmacogenetics 2004, 14:53-60.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/50/pre
pub